A year and a half after scoring an approval to use Keytruda in third-line gastric cancer, Merck has run into a wall trying to apply the PD-1 star in the frontline setting.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,